Investigating the role of RUNX3 in blood vessel remodeling
RUNX3 in Vascular Wall Remodeling
This study is looking at how certain cells in your blood vessels change when they grow too much, which can cause problems like heart disease and high blood pressure, and it will explore the role of a specific protein called RUNX3 to find new ways to help treat these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Ctr at Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project ID | NIH-11006304 on NIH RePORTER |
What this research studies
This research focuses on understanding how vascular smooth muscle cells (VSMCs) change from a stable state to a proliferative state, which can lead to various vascular diseases like atherosclerosis and hypertension. The study will explore the molecular mechanisms behind this change, particularly the role of a protein called RUNX3. By examining how RUNX3 influences VSMC behavior in response to growth factors, the research aims to uncover potential targets for therapeutic intervention. Patients may benefit from insights gained that could lead to new treatments for vascular diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults with conditions related to vascular remodeling, such as atherosclerosis or hypertension.
Not a fit: Patients with vascular diseases not related to smooth muscle cell modulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or treat vascular diseases, improving patient outcomes.
How similar studies have performed: Previous research has shown promising results in understanding the role of transcription factors in vascular diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Tyler, United States
- University of Texas Hlth Ctr at Tyler — Tyler, United States (Active)
Researchers
- Principal investigator: Guo, Xia — University of Texas Hlth Ctr at Tyler
- Study coordinator: Guo, Xia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.